Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 11/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 9/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145557 | 0.90 | SYK (0.43) | RPS6KA2RPS6KA3SYKAURKBINCENP | |
| SCHEMBL4139602 | 0.90 | RPS6KA2 (0.38) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL4144595 | 0.87 | RPS6KA3 (0.36) | RPS6KA2RPS6KA3MAPKAPK2SYKKDM5C | |
| SCHEMBL4146046 | 0.86 | RPS6KA3 (0.42) | RPS6KA2RPS6KA3MAPKAPK2KDM4C | |
| SCHEMBL3092096 | 0.83 | RPS6KA2 (0.45) | RPS6KA2RPS6KA3 | |
| SCHEMBL4144627 | 0.83 | RPS6KA2 (0.39) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL3083810 | 0.77 | RPS6KA3 (0.41) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL3081006 | 0.77 | RPS6KA2 (0.41) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL3079143 | 0.73 | GPR84 (0.42) | RPS6KA2RPS6KA3SYK | |
| SCHEMBL3095189 | 0.72 | GPR84 (0.40) | RPS6KA2RPS6KA3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | RPS6KA2 2578/4885RPS6KA3 1194/4885MAPKAPK2 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.